Adults and children aged two years and above should receive one single dose of Prevenar 13 into the shoulder muscle. This was true for five of the six additional polysaccharides in the second study. All six of the additional polysaccharides in Prevenar 13 produced a response that was similar to the response seen with Prevenar against the seven polysaccharides. pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed). The fourth study in adults over 65 years of age showed that Prevenar 13 reduced the incidence of pneumonia by almost half: 49 out of 42,240 (around 0.1%) subjects fell ill with pneumonia caused by S. pneumoniae in the vaccine group, compared with 90 out of 42,256 (around 0.2%) subjects in the placebo group. In both studies, Prevenar 13 was compared with a similar vaccine containing the polysaccharides from 23 different types of S. pneumoniae (23-valent polysaccharide vaccine). A fourth study involved approximately 85,000 adults over 65 year of age who had not previously been vaccinated with the 23-valent polysaccharide vaccine, and compared Prevenar 13 with placebo (a dummy treatment). The fourth dose, the booster, is given between 11 and 15 months of age. children aged between six weeks and six months are normally given four doses. This helps to protect against the disease. The first study involved 835 adults aged 50 to 64 years who had not previously been vaccinated against invasive disease caused by S. pneumoniae. You are therefore advised to be selective about which sections or pages you wish to print. Prevenar 13 is used to protect children aged between six weeks and 17 years against invasive disease, pneumonia (infection of the lungs) and acute otitis media (infection of the middle ear) caused by S. pneumoniae. The main measure of effectiveness was based on the number of subjects who developed a first episode of pneumonia caused by a type of S. pneumoniae covered by Prevenar 13. Adults aged 18 to 49 had an immune response with Prevenar 13 which was as good as the response in adults aged 60 to 64. All six of the additional polysaccharides in Prevenar 13 produced a response at least as good as the lowest response seen with Prevenar in the first main study. The additional studies showed that Prevenar 13 led to an increase in antibody production following booster vaccinations and supported a switch to Prevenar 13 in children who had started vaccination with Prevenar. In adults aged 50 and older, in the first two main studies Prevenar 13 produced an immune response that was at least as good as the 23-valent polysaccharide vaccine for all 12 of the S. pneumoniae polysaccharides they share in common, and for several of these serotypes the immune response was better with Prevenar 13. A third study, which involved 900 adults aged 18 to 49, compared the immune response to Prevenar 13 with the response in adults aged 60 to 64. In the first two studies they were compared directly, and in the third study the results for Prevenar 13 were compared to those obtained for Prevenar in a previous study. In adults, Prevenar 13 was investigated in four main studies. In Europe, it is estimated that these are responsible for between 73 and 100% of the cases of invasive disease in children under the age of five years, and at least 50 – 76% of the cases of invasive disease in adults, depending on the country. A risk management plan has been developed to ensure that Prevenar 13 is used as safely as possible. In children aged between five and 17 years old, Prevenar 13 produced a response that was at least as good as Prevenar for all seven S. pneumoniae polysaccharides they share in common. The vaccine is also ‘adsorbed’ (fixed) onto an aluminium compound to enhance the immune response. Where the response to Prevenar 13 was lower than the comparator, the differences were considered to be small. Vaccines work by ‘teaching’ the immune system (the body’s natural defences) how to defend itself against a disease. It is available as a suspension for injection that contains parts from 13 different types of the bacterium Streptococcus pneumoniae (S. pneumoniae). Prevenar 13 must not be used in people who are hypersensitive (allergic) to the active substances, to any of the other ingredients or to diphtheria toxoid (a weakened toxin from the bacterium that causes diphtheria). If you want to ask a question or request information from EMA, please Send a question to the European Medicines Agency. Prevenar 13 is used to protect children aged between six weeks and 17 years against invasive disease, pneumonia (infection of the lungs) and acute When prescribing Prevenar 13, consideration should be given to the risk of invasive disease and pneumonia in the different age groups, other diseases the. The European Commission granted a marketing authorisation valid throughout the European Union for Prevenar 13 on 9 December 2009. The second study involved 938 adults aged 70 years or older who had already been vaccinated against invasive disease caused by S. pneumoniae at least five years earlier. Prevenar 13 contains the polysaccharides from 13 different types of S. pneumoniae (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F). The vaccine can only be obtained with a prescription. Annex IIA - Manufacturing-authorisation holder responsible for batch release. Prevenar 13 contains small amounts of polysaccharides (a type of sugar) extracted from the ‘capsule’ that surrounds the S. pneumoniae bacterium. In adults and the elderly, the most common side effects (seen in more than 1 patient in 10) are decreased appetite, headaches, diarrhoea, fever (only very common in adults aged 18 to 29 years), vomiting (only very common in adults aged 18 to 49 years), rash, reactions at the site of injection, limitation of arm movement, arthralgia and myalgia (joint and muscle pain), chills and fatigue. The immune response to the additional six polysaccharides in Prevenar 13 was compared with the lowest immune response to any of the polysaccharides in Prevenar. For the prevention of pneumonia, although the use of Prevenar 13 was only investigated in adults over 65 years of age, the CHMP considered that the results could also be applied to younger adults as studies have shown that their immune response is similar or higher than that among adults older than 65. The vaccination schedule depends on the age of the child and should be based on official recommendations: Prevenar 13 can be used in children who have started vaccination with Prevenar (another vaccine authorised in the European Union for S. pneumoniae, which contains parts of seven of the 13 types of S. pneumoniae included in Prevenar 13). In children below two years of age, the vaccine is given by injection into the thigh muscle. This is a summary of the European public assessment report (EPAR) for Prevenar 13. Prevenar 13 is a vaccine. The studies compared the immune response for Prevenar 13 with that for Prevenar against the seven polysaccharides that they share in common. Invasive disease occurs when the bacterium spreads through the body causing serious infections such as septicaemia (blood infection) and meningitis (infection of the membranes around the brain and spine). In adults and the elderly, the Committee noted that community-acquired pneumonia and invasive pneumococcal disease may be an important health problem and that the benefit in terms of protection outweighed the risk of adverse reactions. Alternatively, when Prevenar 13 is given as part of a routine immunisation programme, two doses can be given at the ages of two and four months, followed by a booster at 11 to 15 months of age; children aged between seven months and 11 months should first receive two doses with an interval of at least one month followed by a third dose in the second year; children between 12 and 23 months of age should receive two doses with an interval of at least two months; children between two and 17 years of age should receive a single dose. In children, the ability of Prevenar 13 to trigger the production of antibodies (immunogenicity) was assessed in two main studies involving 1,266 healthy children who were vaccinated between the ages of two and 15 months and in a third study involving 598 children aged between five and 17 years old who had previously been vaccinated with Prevenar or who had never been vaccinated for invasive pneumococcal disease. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Prevenar 13, including the appropriate precautions to be followed by healthcare professionals and patients. The first three doses are given with an interval of one month between each dose. Prevenar 13 was not shown to affect the immunogenicity of other vaccines routinely given to children. Prevenar 13 is very similar to Prevenar but contains six additional polysaccharides from serotypes which are responsible for between 16 and 60% of the cases. European Medicines AgencyDomenico Scarlattilaan 61083 HS AmsterdamThe Netherlands. The studies compared the immune responses one month after vaccination with the two vaccines. For the full list of all side effects reported with Prevenar 13, see the package leaflet. Active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to 17 years of age. When prescribing Prevenar 13, consideration should be given to the risk of invasive disease and pneumonia in the different age groups, other diseases the vaccinees may have and the type of bacteria in the different geographical areas. Prevenar 13 was compared with Prevenar. Additional studies in children looked at the effects of giving booster vaccinations, switching from Prevenar to Prevenar 13 and using Prevenar 13 alongside other vaccines routinely given to children. Please note that the size of the above document can exceed 50 pages. It is also used to protect adults and the elderly against invasive disease and pnemonia caused by S. pneumoniae. For more information about treatment with Prevenar 13, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. This medicine is authorised for use in the European Union. Please do not include any personal data, such as your name or contact details. When a person is given the vaccine, the immune system recognises the parts of the bacterium contained in the vaccine as ‘foreign’ and makes antibodies against them. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Prevenar 13. The CHMP decided that Prevenar 13’s benefits are greater than its risks and recommended that it be granted marketing authorisation. Further information on the use of Prevenar 13 in people at increased risk of pneumococcal infections (such as patients with HIV or people who have received a haematopoietic stem cell transplant) and on how to switch from Prevenar to Prevenar 13 can be found in the summary of product characteristics (also part of the EPAR). These polysaccharides have been purified, then ‘conjugated’ (attached) to a carrier to help them to be recognised by the immune system. More detail is available in the summary of product characteristics, Boulevard de la Plaine 171050 BruxellesBelgium, 24/06/2021 Prevenar 13 - EMEA/H/C/001104 - P46/064. The immune system will then be able to produce antibodies more quickly when it is exposed to the bacterium. The CHMP noted that in children the immune system’s response to Prevenar 13 was comparable to that of Prevenar, which is already authorised for the protection of children against S. pneumoniae in the EU. Changes since initial authorisation of medicine, Initial marketing-authorisation documents, Committee for Medicinal Products for Human Use, Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 January 2015, Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2013, Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2012, Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 September 2011, Prevenar 13: Paediatric investigation plan, Send a question to the European Medicines Agency, International non-proprietary name (INN) or common name, Anatomical therapeutic chemical (ATC) code, Date of issue of marketing authorisation valid throughout the European Union. Active immunisation for the prevention of invasive disease caused by Streptococcus pneumoniae in adults ≥18 years of age and the elderly.See sections 4.4 and 5.1 for information on protection against specific pneumococcal serotypes.The use of Prevenar 13 should be determined on the basis of official recommendations taking into consideration the risk of invasive disease in different age groups, underlying comorbidities as well as the variability of serotype epidemiology in different geographical areas. People who have a severe fever should not receive the vaccine until they have recovered, but they can still be given the vaccine if they have a mild infection such as a cold.
Ocot Je Kysly Alebo Zasadity, Predam Chladnicku Detva, Maderoterapia Kurz Bratislava, Talianske Cestoviny So Syrovou Omackou, Sociálna Práca A Sociálne Služby, Coca Cola Plechovka Cena, Spravovanie Bytových Domov, Hotel Olymp Martin Cena, Tlak Vzduchu Při Lakování,
Recent Comments